CA2273847C - Diagnostic d'etat pathologique a l'aide de profils d'arn messager - Google Patents

Diagnostic d'etat pathologique a l'aide de profils d'arn messager Download PDF

Info

Publication number
CA2273847C
CA2273847C CA2273847A CA2273847A CA2273847C CA 2273847 C CA2273847 C CA 2273847C CA 2273847 A CA2273847 A CA 2273847A CA 2273847 A CA2273847 A CA 2273847A CA 2273847 C CA2273847 C CA 2273847C
Authority
CA
Canada
Prior art keywords
level
psa
pcr
rna
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2273847A
Other languages
English (en)
Other versions
CA2273847A1 (fr
Inventor
David Ralph
Gang An
Mark O'hara
Robert Veltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratory Corp of America Holdings
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CA2273847A1 publication Critical patent/CA2273847A1/fr
Application granted granted Critical
Publication of CA2273847C publication Critical patent/CA2273847C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention, qui a trait à des méthodes diagnostiques permettant de déceler des états pathologiques chez l'homme, décrit également les sondes génétiques et les techniques afférentes utilisées pour déceler des états pathologiques et surveiller leur évolution. Elle concerne, plus particulièrement, des sondes et des techniques permettant d'évaluer la présence d'espèces d'ARN dont l'expression dans le sang périphérique de personnes souffrant desdits états pathologiques diffère de celle ayant lieu chez des individus en bonne santé. L'invention porte, en outre, sur un modèle de diagnostic à plusieurs variables s'appliquant au cancer de la cancer de la prostate chez des sujets dont le taux plasmatique total d'antigène prostatique spécifique (PSA) est modérément élevé (? 2,0 ng/ml). Les résultats de dosages sériques concernant le produit génique UC325 [Interleukine-8(IL-8)], le taux plasmatique total d'antigène prostatique spécifique (t-PSA) ainsi que les rapports relatifs à l'absence de PSA/PSA total (f/t PSA) ont été combinés pour renforcer la sensibilité du diagnostic du cancer de la prostate dans une population relevant de l'urologie diagnostiquée comme étant atteinte, soit d'un cancer de la prostate limité à l'organe proprement dit (stade clinique A et B), soit d'un cancer de la prostate non limité à l'organe (stade clinique C ou D) ou encore d'une hyperplasie prostatique bénigne (BPH). L'invention traite également des possibilités supplémentaires qu'offre la connaissance des taux sériques en produit génique UC325 de définir avec exactitude les stades d'évolution du cancer de la prostate, indépendamment des taux de PSA, qu'il s'agisse de t-PSA ou de f/t PSA.
CA2273847A 1996-12-06 1997-12-05 Diagnostic d'etat pathologique a l'aide de profils d'arn messager Expired - Fee Related CA2273847C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3261996P 1996-12-06 1996-12-06
US60/032,619 1996-12-06
US3270196P 1996-12-12 1996-12-12
US60/032,701 1996-12-12
US4157697P 1997-03-24 1997-03-24
US60/041,576 1997-03-24
PCT/US1997/022105 WO1998024935A1 (fr) 1996-12-06 1997-12-05 DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER

Publications (2)

Publication Number Publication Date
CA2273847A1 CA2273847A1 (fr) 1998-06-11
CA2273847C true CA2273847C (fr) 2013-08-13

Family

ID=27364173

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2273847A Expired - Fee Related CA2273847C (fr) 1996-12-06 1997-12-05 Diagnostic d'etat pathologique a l'aide de profils d'arn messager

Country Status (4)

Country Link
EP (1) EP0960214A4 (fr)
AU (1) AU722819B2 (fr)
CA (1) CA2273847C (fr)
WO (1) WO1998024935A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
CA2702148C (fr) * 1999-01-06 2014-03-04 Genenews Inc. Methode de profilage de l'expression genique d'un sujet humain atteint d'une maladie infectieuse
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
FI990382A0 (fi) * 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
ATE364721T1 (de) * 1999-06-28 2007-07-15 Source Precision Medicine Inc Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CA2387035A1 (fr) * 1999-10-13 2001-04-19 Sequenom, Inc. Methodes de generation de bases de donnees et bases de donnees pour l'identification de marqueurs genetiques polymorphes
AU2002241720A1 (en) * 2000-11-08 2002-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2002241520A1 (en) * 2000-11-28 2003-03-03 University Of Cincinnati Blood assessment of injury
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003023056A2 (fr) 2001-09-12 2003-03-20 F. Hoffmann-La Roche Ag Marqueurs specifiques a la sclerose en plaques
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
GB0200595D0 (en) * 2002-01-11 2002-02-27 Oxford Glycosciences Uk Ltd Quantitation of differential expression
CA2498418A1 (fr) * 2002-09-10 2004-03-25 Guennadi V. Glinskii Methodes de segregation de genes et de classification d'echantillons biologiques
CN1751129B (zh) * 2002-12-19 2014-07-23 生命科技公司 利用基因表达图谱鉴定、监测和治疗传染病和表征传染病相关炎症
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
CA2544708A1 (fr) * 2003-11-03 2005-05-12 Genenews, Inc. Biomarqueurs du cancer du foie
WO2005098050A2 (fr) 2004-03-26 2005-10-20 Sequenom, Inc. Clivage specifique de base de produits d'amplification specifiques de la methylation en combinaison avec une analyse de masse
GB0510352D0 (en) * 2005-05-20 2005-06-29 Optomed As Methods of prostate cancer diagnosis and prostrate tumour analysis
AU2006259306B2 (en) 2005-06-16 2012-02-16 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis
WO2007018309A1 (fr) * 2005-08-11 2007-02-15 Banyu Pharmaceutical Co., Ltd. Procédé d’évaluation d’un composé à l’aide d’une molécule sur le trajet rb comme indice et procédé de diagnostic moléculaire
WO2007038754A2 (fr) 2005-09-27 2007-04-05 Source Mdx Profilage d'expression genique aux fins de surveillance de l'identification et de traitement de la polyarthrite rhumatoide
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
AU2009268659A1 (en) 2008-07-08 2010-01-14 Genomic Health, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
CA2748823A1 (fr) 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Profilage d'expression genique pour l'identification, la surveillance et le traitement du cancer de la prostate
EP2407555A1 (fr) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Procédés et kits pour le diagnostic du cancer de la prostate
EP2407554A1 (fr) 2010-07-14 2012-01-18 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Procédés et kits pour le diagnostic du cancer de la prostate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
GB2250993B (en) * 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
JPH08502889A (ja) * 1992-10-29 1996-04-02 トーマス・ジェファーソン・ユニバーシティ 前立腺癌の微小転移を検出する方法
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
GB9423912D0 (en) * 1994-11-26 1995-01-11 Imp Cancer Res Tech Detecting tumours
EP0951567B1 (fr) * 1996-09-06 2006-06-14 The Trustees Of Columbia University In The City Of New York Utilisation d'un gene induisant une tumeur prostatique pour detecter des cellules cancereuses
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules

Also Published As

Publication number Publication date
AU5515198A (en) 1998-06-29
AU722819B2 (en) 2000-08-10
EP0960214A4 (fr) 2004-08-04
CA2273847A1 (fr) 1998-06-11
EP0960214A1 (fr) 1999-12-01
WO1998024935A1 (fr) 1998-06-11

Similar Documents

Publication Publication Date Title
CA2273847C (fr) Diagnostic d'etat pathologique a l'aide de profils d'arn messager
US6190857B1 (en) Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6090559A (en) Biomarkers for the detection of prostate cancer
CA2744096C (fr) Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US6218529B1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
TWI503416B (zh) 檢測膀胱癌之尿液標記物
US8551700B2 (en) Diagnostic and prognostic tests
WO2003021229A2 (fr) Tests diagnostiques et pronostiques
US20090215058A1 (en) Methods for screening, predicting and monitoring prostate cancer
US20040241707A1 (en) Enhanced diagnostic potential of prostate-specific antigen expressing cells
US20040253622A1 (en) Androgen regulated prostate specific polypeptide-5 (ARP-5)
JP2004503261A (ja) 分子マーカー
CA2328377A1 (fr) Nouveau procede de diagnostic, de surveillance et de stadification du cancer de la prostate
US7332270B1 (en) Diagnosis of disease state using mRNA profiles in peripheral leukocytes
Karavitaki et al. Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy
AU2017254960B2 (en) Urine markers for detection of bladder cancer
AU2011236061B2 (en) Urine markers for detection of bladder cancer
KR20200104106A (ko) 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커
AU712403B2 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO2002081656A2 (fr) Potentiel diagnostique ameliore de cellules exprimant l'antigene specifique de la prostate
KR20210040921A (ko) 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161205